Cargando…
Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation
Long-term administration of classic immunosuppressants can induce severe adverse effects. The development of novel immunosuppressants confronts great challenges and opportunities. Ibrutinib, an approved drug for B-cell lineages and chronic graft versus host disease (cGVHD), exhibits immunosuppressiv...
Autores principales: | Zhang, Qing, Chen, Jicheng, Gao, Hanchao, Zhang, Song, Zhao, Chengjiang, Zhou, Cuibing, Wang, Chengjun, Li, Yang, Cai, Zhiming, Mou, Lisha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097265/ https://www.ncbi.nlm.nih.gov/pubmed/30123049 http://dx.doi.org/10.7150/ijms.24460 |
Ejemplares similares
-
Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023) -
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19
por: Kaliamurthi, Satyavani, et al.
Publicado: (2021) -
Ibrutinib repurposing: from B-cell malignancies to solid tumors
por: Massó-Vallés, Daniel, et al.
Publicado: (2016) -
Production of α1,3-galactosyltransferase and cytidine monophosphate-N-acetylneuraminic acid hydroxylase gene double-deficient pigs by CRISPR/Cas9
and handmade cloning
por: GAO, Hanchao, et al.
Publicado: (2016) -
Circulating Organ-Specific MicroRNAs Serve as Biomarkers in Organ-Specific Diseases: Implications for Organ Allo- and Xeno-Transplantation
por: Zhou, Ming, et al.
Publicado: (2016)